linjc16/ctgov huggingface dataset:
Retrospective Analysis of capsaïcin Patch in Complex Regional Pain Syndrome

Study Overview
=================
Brief Summary
-----------------
Complex regional pain syndrome is a painful syndrome often secondary to a traumatic lesion. Treatment is difficult, of long duration with variable outcomes. Patch of capsaïcin has been proposed as adjuvant to a multimodal treatment. Capsaïcin may act by its effect on transient receptor potential vanilloid 1. Efficacity and outcome studies with this treatment are lacking. The aim of this retrospective study is to evaluate pain intensity over time assessed by visual analog scale in patient with complex regional pain syndrome treated with capsaïcin patch in addition to their usual treatment.

Official Title
-----------------
Capsaïcin patch8% in Adult Complex Regional Pain Syndromes: a Retrospective Analysis

Conditions
-----------------
Complex Regional Pain Syndromes

Intervention / Treatment
-----------------
* Drug: Capsaïcine patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with complex regional pain syndrome on maximum medical treatment Age ≥18 years Patients treated between 2012 and August 31, 2022 in the pain clinic of the CHU Brugmann Exclusion Criteria: - incomplete medical chart

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Capsaïcine patch|Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity | Pain intensity evaluated by a visual analog scale (on a scale 0 to 10) by patients before and after capsaïcin addition. | 3 month period |
Interest of Re-oxygenation After Inhalation of 50% Nitrous Oxide / 50% Oxygen Premix in Dental Cares

Study Overview
=================
Brief Summary
-----------------
The usefulness of re-oxygenation after inhalation of 50% nitrous oxide and 50% oxygen premix (Kalinox 170 bar) during dental care is studied and the pollution resulting from administration of Kalinox is also investigated.

Official Title
-----------------
Validation of a Kalinox's Administration Protocol for Dental Cares : Interest of Re-oxygenation and Pollution Control

Conditions
-----------------
Dental Cares Under Kalinox's Inhalation

Intervention / Treatment
-----------------
* Drug: Oxygène
* Drug: Air Médical


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: From 1 year old anxious or phobic patients very young children requiring selective dental cares mental deficient patients ASA 1 or ASA 2 patients Exclusion Criteria: ASA 3 or ASA 4 patients contraindication linked to the experimental product patients with mental disorder incompatible with the motory test patients that have received anxiolytic treatment less than 2 hours before the dental care

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Oxygène | Drug: Oxygène<br>* Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation<br>|
| Placebo Comparator: B<br>Air Médical | Drug: Air Médical<br>* Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of SpO2 |  | In continuous | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of ambient air pollution by nitrous oxide and patient's acceptance |  | In continuous |
Study to Evaluate the Feasibility of Integrating the Point-of-care Testing for Sexually Transmitted Infections and HIV Into Community-based Clinics for MSM and TGW in Thailand

Study Overview
=================
Brief Summary
-----------------
This will be a prospective study that will enroll up to 2000 MSM and TG from community-based clinics in Bangkok, Chonburi, Chiang Mai, and Songkhla.

Detailed Description
-----------------
Eligible participants will be followed up until the completion of a 12-month period. All participants will be followed up every 3 months. An additional follow up visit at month 1 will be made for participants who PrEP is initiated at entry visit (those who already received PrEP prior to the study will not need the additional visit). Study Sites The study will take place at the following community-based clinics: SWING DIC, Bangkok, Thailand RSAT DIC, Bangkok, Thailand SWING DIC, Chonburi, Thailand Sisters DIC, Chonburi, Thailand Mplus DIC, Chiang Mai, Thailand RSAT DIC, Songkhla, Thailand

Official Title
-----------------
The Thai Red Cross AIDS Research Centre

Conditions
-----------------
Men Who Have Sex With Men and Transgender Women

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thai nationality Age ≥ 18 years old Men or transgender women who have sex with men Have at least one of the following risks for HIV acquisition in the past 6 months: Any unprotected receptive anal sex More than 5 sexual partners, regardless of condom use and serostatus History of syphilis, chlamydia or gonorrhea diagnosed or treated Any stimulant drug use Have signed the consent form Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>- 800 existing clients who already received PrEP | |
| Group 2<br>800 new clients who present for HIV testing and are HIV-negative. All will be offered PrEP 600 clients who will refuse PrEP 200 clients who will receive PrEP | |
| Group 3<br>- 400 new clients who are HIV-positive or new clients who present for HIV testing and are HIV-positive | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants who receive same-day diagnosis and treatment of CT/NG in community-based clinics |  | 1 years | 
| Proportion of participants who receive same-day diagnosis of HIV infection in community-based clinics |  | 1 years |
Evaluation of Biliary Reflux After Mini-gastric Bypass With Using the Biliary Reflux Index

Study Overview
=================
Brief Summary
-----------------
MGB is considered to be the best alternative to Roux-en-Y gastric bypass (RYGB) due to the shorter operation time and fewer possible complications. The purpose of this study was to determine biliary reflux in patients undergoing MGB/OAGB with a hand-sewn gastroenteroanastomosis, and MGB/OAGB with a stapler gastroenteroanastomosis.

Official Title
-----------------
Evaluation of Biliary Reflux After Mini-gastric Bypass With Using the Biliary Reflux Index

Conditions
-----------------
Ulcer, Gastric, Bile Reflux

Intervention / Treatment
-----------------
* Diagnostic Test: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: morbid obesity BMI above 35 kg/m2 with obesity related comorbidity BMI above 40 kg/m2 undergoing MGB/OAGB no bile reflux during preoperative period Exclusion Criteria: revisional operations therapy-resistant bile reflux during preoperative period history of bariatric surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: hand-sewn gastroenteroanastomosis<br> | Diagnostic Test: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index<br>* fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index<br>|
| Active Comparator: stapler gastroenteroanastomosis<br> | Diagnostic Test: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index<br>* fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success | Determination of the BRI index in patients undergoing MGB/OAGB can be used as a screening method for diagnosing biliary reflux in order to prevent and develop tactic for further management of patients from a risk group of complications associated with the toxic effects of an aggressive bile | 12 month |
The Impact of Experienced Endoscopy Nurse Participation on Polyp and Adenoma Detection During Colonoscopy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether experienced endoscopy nurse participation during screening colonoscopy could increase polyp and adenoma detection rate.

Official Title
-----------------
Can Experienced Endoscopy Nurse Participation During Screening Colonoscopy Increase Polyp and Adenoma Detection Rate?:A Prospective Randomized Trial

Conditions
-----------------
Polyp, Adenoma

Intervention / Treatment
-----------------
* Procedure: Colonoscopist only
* Procedure: Experienced Endoscopy Nurse Participation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 40-70 average risk screening colonoscopy Exclusion Criteria: GI Bleeding ; history of colorectal surgery ; inflammatory bowel disease ; colorectal cancer,or polyposis syndrome

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: endoscopist only<br>Single inspection by endoscopist during colonoscopy | Procedure: Colonoscopist only<br>* Only Colonosopist Observe during Colonoscopy (single observer)<br>Procedure: Experienced Endoscopy Nurse Participation<br>* Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)<br>|
| Experimental: nurse participation<br>Dual inspection by both an endoscopist and an experienced nurse during colonoscopy | Procedure: Colonoscopist only<br>* Only Colonosopist Observe during Colonoscopy (single observer)<br>Procedure: Experienced Endoscopy Nurse Participation<br>* Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Polyp detection rate |  | 1.5 year | 
| adenoma detection rate |  | 1.5 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Advanced polyp detection rate |  | 1.5 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nurse; Colonoscopy; Polyp; Adenoma;
Aortic Dimensions in Turner Syndrome

Study Overview
=================
Brief Summary
-----------------
An observational study of 102 women with Turner syndrome followed for 6 years with a two-yearly examination including ECHO, MRI of the heart and 24 ambulatory blood pressure. It has been found that besides an significantly increased risk of congenital cardiac malformations, TS have an increased risk of developing cardiac disease including the life threatening condition of aortic dilatation and rupture. The aim of the study is to describe the cardiac conditions of TS, evaluate different methods of examination and identify possible risc factors.

Official Title
-----------------
Aortic Dimensions, 24hour Ambulatory Blood Pressure and Sympathovagal Tone in Turner Syndrome. In Relation to Aortic Dilatation and Dissection.

Conditions
-----------------
Turner Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Turner syndrome Age 18-70 years Exclusion Criteria: Extreme adipositas Contraindications to a MRI scan Malignant disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>women with Turner syndrome | |
| 2.<br>Control women | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aortic diameter at 3 well-defined levels measured by MRI and ECHO |  | 2-yearly for 6 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 24hour ambulatory blood pressure |  | 24h 2-yearly for 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Turner syndrome, aortic dimensions, blood pressure, aortic dilatation, aortic rupture
Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%

Study Overview
=================
Brief Summary
-----------------
To assess the potential of tretnoin gel 0.05% to produce phototoxic reactions, measured as skin reactions 24 and 48 hours after UV radiation of drug on skin.

Official Title
-----------------
Clinical Evaluation of the Phototoxic Potential of Atralin (Tretinoin) Gel, 0.05%

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Atralin (tretinoin) Gel, 0.05%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal healthy volunteers 18 years of age or older Exclusion Criteria: Less than 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br> | Drug: Atralin (tretinoin) Gel, 0.05%<br>* Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| UV induced skin sensitization |  | 4 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Safety when exposed to sunlight
Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to investigate the bioequivalence of Mylan's liothyronine sodium 50 mcg tablets to King's Cytomel® 50 mcg tablets following a single, oral 100 mcg (2 x 50 mcg) dose administration under fasting conditions.

Official Title
-----------------
Single-Dose Fasting Bioequivalence Study of Liothyronine Sodium Tablets (50 Mcg; Mylan) to Cytomel® Tablets (50 Mcg; King) in Healthy Euthyroid Adult Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: 1: Liothyronine Sodium Tablets
* Drug: 2: Cytomel® Tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy males and/or non-pregnant, non-lactating females, 18 years and older able to swallow medication Exclusion Criteria: institutionalized subjects history of any significant disease use of any prescription or OTC medications within 14 days prior to start of study received any investigational products within 30 days prior to start of study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Liothyronine Sodium Tablets, 50 mcg | Drug: 1: Liothyronine Sodium Tablets<br>* Liothyronine Sodium Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting<br>|
| Active Comparator: 2<br>Cytomel® Tablets, 50 mcg | Drug: 2: Cytomel® Tablets<br>* Cytomel® Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence |  | within 30 days |
Therapeutic Plasma Exchange in Thyrotoxicosis

Study Overview
=================
Brief Summary
-----------------
Therapeutic plasma exchange (TPE) is indicated in cases where antithyroid medications cannot be used due to the side effects or attain no adequate hormonal suppression response at the highest dosage and in cases of rapid onset of clinical symptoms. This study presents the treatment results of patients who underwent TPE and subsequently operated for thyrotoxicosis.

Detailed Description
-----------------
Background: Therapeutic plasma exchange (TPE) is indicated in cases where antithyroid medications cannot be used due to the side effects or attain no adequate hormonal suppression response at the highest dosage and in cases of rapid onset of clinical symptoms. This study presents the treatment results of patients who underwent TPE and subsequently operated for thyrotoxicosis. Methods: The files of 27 patients who underwent preoperative TPE for thyrotoxicosis between January 1999 and February 2019 were retrospectively analyzed. The demographic and clinical features of the patients were included.

Official Title
-----------------
Preoperative Therapeutic Plasma Exchange and Surgical Treatment in Thyrotoxicosis Patients: a Single-centre Retrospective Cohort Study

Conditions
-----------------
Thyrotoxicosis

Intervention / Treatment
-----------------
* Device: Therapeutic plasma exchange


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: thyrotoxicosis unresponsive to medication adverse reaction to the medications need for rapid treatment in patients that need urgent surgery Exclusion Criteria: The patients who did not undergo surgery post-therapeutic plasma exchange Preoperative hypocalcemia, hemodynamically unstable patients patients not suitable for central catheter placement

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Therapeutic plasma exchange|Therapeutic plasma exchange filtrates plasma and decreases thyroid hormone concentration in the blood|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thyroid hormone levels of patients after therapeutic plasma exchange | Concentration of serum thyroid hormone levels before thyroidectomy | 1 week before the operation |
Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg (FSC 100/50) or inhaled corticosteriods in typical clinical practice using a retrospective observational cohort study design of large managed care database.

Official Title
-----------------
Comparison of Healthcare Utilization and Costs in Patients With Asthma Who Fluticasone/Salmeterol Inhalation Powder Versus Other Inhaled Corticosteroid(s) in Typical Clinical Practice Using Health Insurance Claims Data.

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Fluticasone propionate/salmeterol combination
* Drug: Inhaled corticosteroids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with asthma as determined by ICD-9 codes and asthma drug use at least 12 years of age treated with inhaled corticosteroids Exclusion Criteria: Subjects with COPD or treatment for COPD

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Asthma patients treated with inhaled corticosteroids<br>Asthma subjects newly prescribed inhaled corticosteriods | Drug: Fluticasone propionate/salmeterol combination<br>* Asthma subjects newly prescribed fluticasone propionate/salmeterol combination<br>Drug: Inhaled corticosteroids<br>* asthma subjects newly prescribed inhaled corticosteroids in clinical practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the difference in asthma related exacerbations | Asthma related exaceberation is defined as any asthma related emergency department visit, or inpatient visit or oral corticosteroid dispensing. | 90 days post index | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fluticasone propionate/salmeterol combination, Asthma, inhaled corticosteroids, outcomes